172 related articles for article (PubMed ID: 26179902)
1. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
Long J; Chang L; Shen Y; Gao WH; Wu YN; Dou HB; Huang MM; Wang Y; Fang WY; Shan JH; Wang YY; Zhu J; Chen Z; Hu J
J Immunol; 2015 Aug; 195(4):1849-57. PubMed ID: 26179902
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Reddy P; Maeda Y; Hotary K; Liu C; Reznikov LL; Dinarello CA; Ferrara JL
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3921-6. PubMed ID: 15001702
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells.
Okamoto S; Fujiwara H; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Yoshimura A; Tanimoto M; Maeda Y
J Immunol; 2015 Feb; 194(3):1357-63. PubMed ID: 25527789
[TBL] [Abstract][Full Text] [Related]
4. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
[TBL] [Abstract][Full Text] [Related]
5. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
6. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.
Wu Y; Bastian D; Schutt S; Nguyen H; Fu J; Heinrichs J; Xia C; Yu XZ
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1195-204. PubMed ID: 25846718
[TBL] [Abstract][Full Text] [Related]
7. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
[TBL] [Abstract][Full Text] [Related]
9. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
10. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.
Yu Y; Wang D; Liu C; Kaosaard K; Semple K; Anasetti C; Yu XZ
Blood; 2011 Nov; 118(18):5011-20. PubMed ID: 21856864
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
13. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid ameliorates coxsackievirus-B3-induced viral myocarditis by modulating Th17/Treg imbalance.
Jin H; Guo X
Virol J; 2016 Oct; 13(1):168. PubMed ID: 27724948
[TBL] [Abstract][Full Text] [Related]
15. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
[TBL] [Abstract][Full Text] [Related]
16. T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function.
Fu J; Wang D; Yu Y; Heinrichs J; Wu Y; Schutt S; Kaosaard K; Liu C; Haarberg K; Bastian D; McDonald DG; Anasetti C; Yu XZ
J Immunol; 2015 Jan; 194(1):388-97. PubMed ID: 25404360
[TBL] [Abstract][Full Text] [Related]
17. Tetramerization of pyruvate kinase M2 attenuates graft-versus-host disease by inhibition of Th1 and Th17 differentiation.
Wang M; Li QJ; Zhao HY; Zhang JL
Hum Cell; 2024 May; 37(3):633-647. PubMed ID: 38416276
[TBL] [Abstract][Full Text] [Related]
18. GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.
Park MJ; Lee SH; Lee SH; Kim EK; Lee EJ; Moon YM; La Cho M
J Transl Med; 2016 Jul; 14(1):206. PubMed ID: 27391226
[TBL] [Abstract][Full Text] [Related]
19. The protection and therapy effects of bortezomib in murine acute graft-versus-host disease.
Li Z; Wu Q; Yan Z; Li D; Lu G; Mou W; Wu S; Pan X; Lu Q; Xu K
Transplant Proc; 2013; 45(6):2527-35. PubMed ID: 23953575
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
Aharoni R; Schlegel PG; Teitelbaum D; Roikhel-Karpov O; Chen Y; Arnon R; Sela M; Chao NJ
Immunol Lett; 1997 Jul; 58(2):79-87. PubMed ID: 9271317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
